Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benefit-Risk Assessments For Me-Too Drugs Encouraged By FDA

Executive Summary

Sponsors should complete agency’s structured benefit-risk framework to help reviewers better understand the reason the product is needed in the marketplace.

Advertisement

Related Content

Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy
Fibromyalgia Patient Meeting Shines Light On Lesser Known Symptoms
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
PhRMA Testing Pilot Framework For Structured Benefit-Risk Assessment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel